Thermo Fisher Scientific TMO has made notable moves in the
bio-tech market. The company recently
acquired Solventum’s Purification and Filtration Business for
$4.1 billion which is expected to bolster its position in biopharma manufacturing. It also
signed an agreement to acquire Gatan from Roper Technologies. Financially, TMO celebrated a
strong Q4 and predicted consistent profit growth for
2025. The company has also authorized a
$4 billion share repurchase. However, some insider trading indicates skepticism as the Senior VP & General Counsel sold significant shares. Indeed, TMO experienced a dip in Q4 but has also been cited as a
safe dividend stock for beginners and seen os one of the best fundamental stocks to purchase. The company also made significant efforts to foster growth with the
CEOs presentation promising new opportunities in healthcare. Lastly, TMO plans to leverage its newly launched
CorEvitas Clinical Registry and Biorepository to advance research in systemic lupus erythematosus.
Thermo Fisher Scientific TMO News Analytics from Thu, 11 Jul 2024 07:00:00 GMT to Fri, 14 Mar 2025 14:15:12 GMT -
Rating 4
- Innovation 3
- Information 6
- Rumor -3
